[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41(1):3-28.
[2] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-98.
[3] 周路路, 刘娜, 李春霞, 等. 慢性HBV感染免疫控制期的抗病毒治疗[J]. 临床肝胆病杂志, 2020, 36(5):1134-7.
[4] Terrault N A, Lok A S F, McMahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-99.
[5] Sarin S K, Kumar M, Lau G K, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98.
[6] 白萧萧, 东冰, 徐光华. 慢性HBV感染免疫控制期与免疫逃逸期研究进展[J]. 肝脏, 2018, 23(4):344-7.
[7] Wang H, Luo H, Wan X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1): 45-56.
[8] Habersetzer F, Moenne-Loccoz R, Meyer N, et al. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection[J]. Liver Int, 2015, 35(1): 130-9.
[9] Invernizzi F, Viganò M, Grossi G, et al. The prognosis and management of inactive HBV carriers[J]. Liver Int, 2016, 36 Suppl 1: 100-4.
[10] WHO Guidelines Approved by the Guidelines Review Committee[M]. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva; World Health Organization, 2015.
[11] Papatheodoridis G V, Manolakopoulos S, Liaw Y F, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review[J]. J Hepatol, 2012, 57(1): 196-202.
[12] 陈进, 卞冬雪, 叶卫江. 68例非活动性 HBsAg 携带者的肝组织病理及相关危险因素分析[J]. 浙江实用医学, 2013, (6):383-385.
[13] Zhai X, Zhu L, Jiang J, et al. Virological activity in treatment-naïve HBeAg-negative HBV-infected adult patients: A community-based study in Jiangsu, China[J]. Medicine (Baltimore), 2020, 99(29): e21179.
[14] 黄珊, 何清, 唐奇远, 等. 91例非活动性HBsAg携带者肝组织病理特点的研究[J]. 中国病毒病杂志, 2012, 2(01):58-61.
[15] Wu W J, Lin C L, Liu C J, et al. Lifetime risk of liver-related outcomes and determinants in male inactive carriers of chronic hepatitis B[J]. J Med Virol, 2023, 95(10): e29138.
[16] Kuang X J, Jia R R, Huo R R, et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance[J]. J Viral Hepat, 2018, 25(9): 1026-37.
[17] Lin C L, Kao J H. Review article: the prevention of hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2018, 48(1): 5-14.
[18] Gaia S, Marzano A, Olivero A, et al. Inactive hepatitis B virus carriers: a favourable clinical condition[J]. Eur J Gastroenterol Hepatol, 2005, 17(12): 1435-1436.
[19] Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents[J]. Lancet Gastroenterol Hepatol, 2019, 4(6): 466-476.
[20] Chien R N, Liaw Y F. Current Trend in Antiviral Therapy for Chronic Hepatitis B[J]. Viruses, 2022, 14(2):434.
[21] Hsu Y C, Yeh M L, Wong G L, et al. Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B[J]. J Infect Dis, 2021, 224(11): 1890-1899.
[22] Atay K, Hatemi İ, Canbakan B, et al. Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B[J]. Turk J Gastroenterol, 2016, 27(3): 279-283.
[23] Fasano M, Lampertico P, Marzano A, et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years[J]. J Hepatol, 2012, 56(6): 1254-1258.
[24] Jeng W J, Chen Y C, Chien R N, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B[J]. Hepatology, 2018, 68(2): 425-434.
[25] Lok A S, Zoulim F, Dusheiko G, Ghany M G. Hepatitis B cure: From discovery to regulatory approval[J]. J Hepatol, 2017, 67(4): 847-861.
[26] Islam M, Kumar K, Sevak J K, et al. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN[J]. Hepatol Commun, 2023, 7(5):e0098.
[27] Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4): 1058-1066.
[28] Marcellin P, Bonino F, Lau G K, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J]. Gastroenterology, 2009, 136(7): 2169-79.e1-4.
[29] Su Q, Liu Y, Li J. Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B[J]. Medicine (Baltimore), 2018, 97(34): e12089.
[30] Song A, Lin X, Lu J, et al. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis[J]. Front Immunol, 2021, 12: 779347.
[31] Lim SG L G, Dan YY, et al. HBsAg loss in inactive chronic hepatitis B carriers is dependent on level of qHBsAg and interferon response: a randomized control trial[J]. AASLD2019, Abstracts (oral196).
[32] Li M H, Xie Y, Zhang L, et al. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a[J]. World J Hepatol, 2016, 8(15): 637-643.
[33] Zeng Q L, Yu Z J, Shang J, et al. Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels[J]. Open Forum Infect Dis, 2020, 7(6): ofaa208.
[34] 李颍, 徐佳, 王延君, 丁芹. 回顾性分析聚乙二醇干扰素ɑ治疗慢性乙型肝炎HBsAg清除的预测因素分析[J]. 医学研究杂志, 2022, 51(4):109-113.
[35] Ouzan D, Pénaranda G, Joly H, et al. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs[J]. J Clin Virol, 2013, 58(4): 713-717.
[36] Tangkijvanich P, Chittmittraprap S, Poovorawan K, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response[J]. J Viral Hepat, 2016, 23(6): 427-438.
[37] 李金伟. 聚乙二醇干扰素联合富马酸替诺福韦治疗HBeAg阴性慢性乙型肝炎的临床研究[J]. 世界复合医学, 2023, 9(3):164-166,170.
[38] Bahardoust M, Mokhtare M, Barati M, et al. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study[J]. J Infect Chemother, 2020, 26(12): 1265-1271.
[39] Li M H, Yi W, Zhang L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J]. J Viral Hepat, 2019, 26 Suppl 1: 32-41.
[40] Zhang C, Yang Z, Wang Z, et al. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B[J]. Int J Med Sci, 2020, 17(3): 383-389.
[41] Farag M S, van Campenhout M J H, Pfefferkorn M, et al. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B[J]. Clin Infect Dis, 2021, 72(2): 202-211.
[42] Jansen L, Kootstra N A, van Dort K A, et al. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues[J]. J Infect Dis, 2016, 213(2): 224-232.
[43] Limothai U, Chuaypen N, Poovorawan K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(12): 1481-1488.
[44] Yeo Y H, Ho H J, Yang H I, et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis[J]. Gastroenterology, 2019, 156(3): 635-46.e9.
[45] Lai C L, Shouval D, Lok A S, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2006, 354(10): 1011-1020.
[46] Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives[J]. Front Immunol, 2021, 12: 733364.
[47] Wu Y, Liu Y, Lu J, et al. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 514-6.e2.
[48] Song A, Wang X, Lu J, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis[J]. J Viral Hepat, 2021, 28(4): 601-612. |
